Category Archives: Science: Biology

Cutting edge research is happening on a daily basis in our modern world, Keep up to date with our Press Release services.

Science: Biology

20 Companies That Have Worked Out Molecular Diagnostic Deals Recently

Leave a comment



ARLINGTON, Va. (PRWEB)

According to Kalorama Information’s The World Market for Molecular Diagnostics Tests, 11th Edition, the demand for molecular in vitro diagnostics (IVD) means that very often a single firm cannot go it alone and must find partners.

These are partnerships involving 20 companies that have just occurred in recent months:

  • Qiagen Neuron23 an agreement to develop a NGS based companion diagnostic for Neuron23’s brain penetrant leucine-rich repeat kinase (LRRK2) inhibitor for Parkinson’s disease; planned to be developed using the NextSeq 500 System

  • AstraZeneca and Biocartis: development of a novel companion diagnostic test on Biocartis’ molecular Idylla platform, for use with Tagrisso (osimertinib), AstraZeneca’s third-generation EGFR-TKI (tyrosine kinase inhibitor) treatment”

  • Cepheid BioGX: collaboration to deliver a PCR test for monkeypox that will run on the GeneXpert system

  • Exact Sciences Ultima Genomics: Ultima Genomics will provide access to its NGS products, which are based on a new architecture designed to enable sequencing at a fraction of the cost of other technologies; develop one or more of Exact Sciences’ advanced cancer diagnostic tests using Ultima’s sequencing technology; Exact Sciences investing in Ultima

  • Immucor and Pirche: a multi-year partnership to expand Immucor’s transplant diagnostics software; Immucor makes investment in Pirche; goal to provide users a seamless and direct interface with the Pirche epitope matching prediction pipeline in their transplant analysis software

  • QuantuMDx and Sansure Biotech global R&D, manufacturing and commercial partnership aimed to bring a comprehensive array of molecular diagnostic assays to the Q-POC platform; Sansure gets exclusive rights to Q-POC in China, for which QuantuMDx receives licensing and royalty payments; QuantuMDx will have the exclusive rights to sell Sansure-translated assays outside China

  • Bio-Rad and Curiosity Diagnostics acquiring Curiosity for total consideration of up to $170 M, consisting of approximately $100 M in cash, and up to $70 M in future milestone payments

  • Roche and Amoy Diagnostics: strategic partnership; jointly promote the development of an open, cooperative and innovative medical and health ecosystem and provide patients with more accurate digital medical solutions

  • Bio-Rad and 10x Genomics: companies agree to global patent cross-licensing for patents held by Bio-Rad and 10x Genomics, resolving outstanding legal issues in the field of single-cell genomics; non-exclusive, worldwide, royalty-bearing license to develop products and services related to single-cell analysis

  • Meridian Bioscience and SD Biosensor and SJL Partners: definitive merger agreement whereby a newly formed affiliate vehicle of the Consortium will acquire Meridian in an all-cash transaction valued at approximately $1.53 billion.


About Kalorama Information:

Kalorama Information, part of Science and Medicine Group, is the leading publisher of market research in healthcare areas, including in vitro diagnostics (IVD), biotechnology, medical devices, and pharmaceuticals. Science and Medicine Group supports companies seeking to commercialize the rapidly changing marketplace at the intersection of science, medicine, and technology. Comprised of industry-leading brands, Science and Medicine Group serves analytical instrument, life science, imaging, and clinical diagnostic companies by helping them create strategies and products to win markets and provide platforms to digitally engage their markets through a variety of innovative solutions. Kalorama Information produces 30 reports a year. The firm offers a Knowledge Center, which provides access to all published reports.

Share article on social media or email:

Science: Biology

INDIGO Biosciences Receives Approval from California Water Boards for Use of Its Bioassays in Recycled Water Monitoring

Leave a comment


News Image

We look forward to developing additional bioassays that can help water boards and regulators everywhere monitor for contaminants that pose potential environmental and health risks.


STATE COLLEGE, Pa. (PRWEB)

INDIGO Biosciences, Inc. has received approval from the California Water Boards, State Water Resources Control Board, for the use of two of its bioassays in recycled water monitoring. INDIGO has been approved for the use of its Aryl Hydrocarbon Receptor (AhR) and Estrogen Receptor Alpha (ERα) bioassays as bioanalytical screening tools for Constituents of Emerging Concern (CECs) in recycled water.

“Both of these assays were developed by INDIGO’s in-house scientific team,” said Fred Marroni, INDIGO’s President and CEO, “and this approval highlights INDIGO’s scientific expertise in developing screening tools that can help protect the environment and human health. We look forward to developing additional bioassays that can help water boards and regulators everywhere monitor for contaminants that pose potential environmental and health risks.”

As part of the approval process, INDIGO submitted validation packages for both its AhR and ERα assays. Both validation packages demonstrated the utility of the bioassays for use as biological screening tools for CECs as set forth in California’s Recycled Water Policy. These assays are useful in screening for biological activity due to CECs such as estradiol, bisphenol A, nonylphenol, dioxin-like chemicals, polycyclic aromatic hydrocarbons, and pesticides.

INDIGO’s bioassays are also effective in identifying the presence of CECs for which no relevant data is available, such as new compounds that may be entering the market or mixtures of compounds, which may occur in recycled water. The presence of these new compounds and mixtures can be missed by targeted analytical methods. This is important since compounds that interact with these receptors can adversely affect human health including reproductive and developmental issues and have been linked to various types of cancer.

About INDIGO Biosciences, Inc.

INDIGO Biosciences is a leading provider of cell-based luciferase reporter assays. Our products and services are used in a broad range of industries such as environmental, drug discovery, academia, and contract research organizations. INDIGO assays are available as turnkey kits for use by scientists, or INDIGO can perform the assays in our own lab as a service. INDIGO’s assays have been demonstrated to provide fast, accurate, reproducible results, and we are dedicated to supporting scientists through reliable science, easy-to-use products, and a highly qualified technical support team. Learn more at indigobiosciences.com.

Share article on social media or email:

Science: Biology

Mount Sinai Appoints Michal A. Elovitz, MD, as Dean for Women’s Health

Leave a comment


“I am excited to have this opportunity to mentor and sponsor the next generation of promising physician-scientists and scientists in women’s health at Mount Sinai.” -Michal A. Elovitz, MD


NEW YORK (PRWEB)

Michal A. Elovitz, MD, a renowned leader in maternal-fetal medicine and expert in preterm birth, has been named Dean for Women’s Health Research and Director of the Center for the Advancement of Female Biology at the Icahn School of Medicine at Mount Sinai. She will join the school on Wednesday, March 1, 2023.

In these new positions, Dr. Elovitz will advance research into women’s health and female biology across all major departments and institutes within Icahn Mount Sinai, which includes launching new multidisciplinary studies related to women’s health and sex-specific and female biology, and collaborating with The Blavatnik Family Women’s Health Research Institute, the Precision Immunology Institute (PrIISM), and the Black Family Stem Cell Institute.

“I am thrilled to join the Mount Sinai community and look forward to collaborating with exceptional scientists from diverse disciplines across the campus to create foundational programs to advance women’s health science and to make meaningful advances to improve health for women across their lifespan,” said Dr. Elovitz. “I am excited to have this opportunity to mentor and sponsor the next generation of promising physician-scientists and scientists in women’s health at Mount Sinai. I remain committed to promoting equity and empowering women as physicians, scientists, and leaders in medicine and science.”

Dr. Elovitz’s research has focused on understanding the underlying biological mechanisms and consequences of adverse reproductive and pregnancy outcomes and their implications for the long-term health of the mother and child. Her research integrating immunology and microbiology into pregnancy health has led to critical discoveries in predicting and understanding preterm birth. Dr. Elovitz’s research portfolio, which is funded by the National Institute of Child Health and Human Development, the National Institute of Nursing Research, and the National Institute of Allergy and Infectious Diseases, will continue at the Center for the Advancement of Female Biology at Mount Sinai.

“We are immensely proud to recruit one of the world’s leading physicians in women’s health, Michal A. Elovitz, now a trusted and valued colleague,” said Dennis Charney, MD, Anne and Joel Ehrenkranz Dean of Icahn Mount Sinai and President for Academic Affairs of the Mount Sinai Health System. “Dr. Elovitz will continue her more than 20 years of innovative bench-to-bedside research in maternal, reproductive, and child health at Mount Sinai, and with her expertise and knowledge, will lead the charge to seamlessly integrate female biology and women’s health across all facets of learning, scientific discovery, and health care throughout our Health System.”

Dr. Elovitz joins Mount Sinai from the Perelman School of Medicine at the University of Pennsylvania, where she has been the Hilarie L. Morgan and Mitchell L. Morgan President’s Distinguished Professor in Women’s Health and a Professor of Microbiology, as well as founder and Director of the Maternal and Child Health Research Center, Vice Chair for Translational Research, founder and Director of the Prematurity Prevention Program, Director of the Maternal Fetal Medicine Fellowship, and Creator and Lead Mentor of the Women for Women’s Health Mentoring Group.

Dr. Elovitz received her MD from Albert Einstein College of Medicine, and completed her residency in obstetrics and gynecology at NewYork-Presbyterian Hospital/Weill Cornell Medical Center and her fellowship in maternal-fetal medicine at the University of Chicago. She is a longtime active member of the National Institutes of Health peer review process and has served as a reviewer for more than 20 scientific journals; she has authored or co-authored more than 175 peer-reviewed publications. Dr. Elovitz is a member of the American College of Obstetrics & Gynecology, the Society of Maternal Fetal Medicine, and the Society of Reproductive Investigation.

About the Mount Sinai Health System

Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with more than 43,000 employees working across eight hospitals, over 400 outpatient practices, nearly 300 labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time — discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.

Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 7,300 primary and specialty care physicians; 13 joint-venture outpatient surgery centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and more than 30 affiliated community health centers. We are consistently ranked by U.S. News & World Report’s Best Hospitals, receiving high “Honor Roll” status, and are highly ranked: No. 1 in Geriatrics and top 20 in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Neurology/Neurosurgery, Orthopedics, Pulmonology/Lung Surgery, Rehabilitation, and Urology. New York Eye and Ear Infirmary of Mount Sinai is ranked No. 12 in Ophthalmology. U.S. News & World Report’s “Best Children’s Hospitals” ranks Mount Sinai Kravis Children’s Hospital among the country’s best in several pediatric specialties. The Icahn School of Medicine at Mount Sinai is one of three medical schools that have earned distinction by multiple indicators: It is consistently ranked in the top 20 by U.S. News & World Report’s “Best Medical Schools,” aligned with a U.S. News & World Report “Honor Roll” Hospital, and top 20 in the nation for National Institutes of Health funding and top 5 in the nation for numerous basic and clinical research areas. Newsweek’s “World’s Best Smart Hospitals” ranks The Mount Sinai Hospital as No. 1 in New York City and in the top five globally, and Mount Sinai Morningside in the top 30 globally; Newsweek also ranks The Mount Sinai Hospital highly in 11 specialties in “World’s Best Specialized Hospitals,” and in “America’s Best Physical Rehabilitation Centers.”

For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.

Share article on social media or email:

Science: Biology

Atarraya and BiomEdit Announce Research Collaboration to Increase Sustainability of Shrimp Farming and Improve Global Food Security

Leave a comment


Shrimp produced in Atarraya’s Shrimpbox using biofloc technology

“The findings from this research project will help Atarraya to increase the production output of shrimp farming while reducing costs and improving sustainability. Together, we are making shrimp the most sustainable protein choice in global food production.”


INDIANAPOLIS (PRWEB)

Atarraya Inc, creator of Shrimpbox, the first sustainable ‘plug-and-play’ shrimp farming technology, and BiomEdit, a microbiome innovator focused on animal health, today announced a research collaboration to investigate microbial changes to improve the cost-effectiveness, sustainability and production output associated with shrimp farming. The research partnership will focus on nitrifying microbes and vibriosis control, and will study how microbial communities change over time in a shrimp biofloc system to define the homeostasis of the ecosystem created for sustainable shrimp farming.

The goal of Atarraya and BiomEdit’s research collaboration is to gain a better understanding of microbial communities and their correlation with nitrogen spikes and other environmental changes. The knowledge gained from the study will help to minimize water usage, improve the environmental footprint of production and reduce the amount of feed needed to produce shrimp. This will improve the cost-effectiveness of sustainable shrimp farming significantly as feed is responsible for about 50% of shrimp production cost.

“Our collaboration with BiomEdit goes back to the core idea of Atarraya: using deep science knowledge to optimize protein production and contribute to global food security,” said Daniel Russek, CEO and founder of Atarraya. “The findings from this research project will help Atarraya to increase the production output of shrimp farming while reducing costs and improving sustainability. Together, we are making shrimp the most sustainable protein choice in global food production.”

Atarraya and BiomEdit expect to learn more about the ecosystem in aquaculture by using advanced microbiological tools to analyze the composition and diversity of microorganisms that inhabit the shrimp pond, as well as their interactions with each other and their environment.

“The Microbiome project will allow a deeper understanding of the role of the microbial community in maintaining crop homeostasis,” explains André Freitas, Biotech Director, Atarraya Inc. “The future of modern aquaculture is based on the use of innovative technology applied to high productivity systems, rational use of water and production of premium quality protein. Shrimp farming in a biofloc system is the face of this new aquaculture.”

Atarraya’s shrimp farming technology uses biofloc technology to transform waste nutrients into feed with the help of microorganisms. As part of the research collaboration, BiomEdit will use its gene-sequencing platform to provide critical insights into the roles of various microorganisms in the growth cycle of shrimp through high-throughput strain isolation and characterization. The approach is especially critical in land-based aquaculture systems with low environmental impact and increases the reliability of shrimp protein production. The research findings will be used to inspire strategies that optimize the health and performance of aquaculture shrimp production.

As one of the most popular proteins in the world, shrimp plays a key role in feeding a growing global population. In the past five years, shrimp sales volume increased from 275 to 415 million pounds. Yet, conventional methods of shrimp farming are disastrous for the environment – destroying seabeds and polluting oceans. Housed in a traditional shipping container, Shrimpbox by Atarraya is the key to meeting the growing demand for shrimp by increasing production while minimizing the impact on the planet.

“We are pleased to collaborate with Atarraya to find new ways to unlock the potential of the microbiome for shrimp producers who are trying to increase production and reduce their environmental footprint to meet the demands of a growing population,” said Aaron Schacht, CEO of BiomEdit. “Our deep knowledge in the microbiome in livestock paired with Atarraya’s immense expertise in shrimp and aquaculture production systems form an ideal match to optimize the use of biofloc.”

About Atarraya

Atarraya is on a mission to make shrimp the sustainable protein of the 21st century. Powered by AI, Atarraya’s proprietary Shrimpbox is a true “plug and play” sustainable shrimp farm that transforms aquaculture by using the most advanced biotechnology, software and hardware available. Atarraya’s Shrimpbox technology was developed over the course of the past 10 years by a team of engineers, biologists, and developers from Mexico, Norway, Brazil, Argentina and Poland. Atarraya’s holdings include Maricultura Vigas, a sustainable aquaculture production company with a decade of shrimp farming experience utilizing biofloc technology that minimizes the use of water and eliminates the necessity of antibiotics and harmful chemicals.

Based in Mexico City and Indianapolis, Atarraya is a privately held corporation backed by Jeffrey Horing, Mark K. Gormley and other angel investors. Follow Atarraya on YouTube, LinkedIn and Twitter, or learn more at https://www.atarraya.ai.

About BiomEdit

Founded in 2022 and headquartered in Fishers, Indiana, BiomEdit discovers, designs and develops novel probiotics, microbiome-derived bioactives and engineered microbial medicines to address unmet needs in animal health. We partner with Ginkgo Bioworks to amplify and accelerate product discovery and development with a goal of introducing breakthrough innovation for livestock producers and veterinarians. BiomEdit is Microbiome Innovation in Animal Health. For more information, visit us at linkedin.com/company/biomeditanimalhealth.

All trademarks contained herein are the property of their respective owners.

###

Share article on social media or email:



Science: Biology

New WorldCat.org connects genealogy enthusiasts, educators, and historians to the world’s libraries

Leave a comment



DUBLIN, Ohio (PRWEB)

For genealogy enthusiasts, educators, and historians, the new WorldCat.org offers an improved experience to uncover family lineages and investigate historical events. By exploring the billions of library resources from more than 10,000 libraries worldwide represented on WorldCat.org, users can find an unparalleled pool of genealogical information.

“Genealogy research provides powerful and meaningful points of access into self-awareness and discovery of the world around us,” said Skip Prichard, President and CEO of OCLC, a global library nonprofit that’s been an innovator in library technology and research for more than 50 years. “WorldCat.org makes visible one of the most important research tools—the world’s libraries—making it a go-to source for detailed genealogical research.”

As more and more hobbyists and professionals alike seek to learn about the stories that precede and interweave with their own, WorldCat.org has a breadth and depth of information that can’t be found anywhere else online. Through WorldCat.org, people can identify a variety of source materials in libraries around the world, including:


  • Newspapers

  • Photographs

  • Family Bibles, church histories, and records

  • Cemetery and burial records

  • Military records

  • Town histories and probate records

  • General genealogical resources, such as directories, handbooks, and magazines

  • Slavery and antislavery materials, including slave records

  • Indexes of births, marriages, deaths, wills, and obituaries

  • Microfilmed genealogy and local history collections


FamilySearch has been working with OCLC to not only expand access to FamilySearch’s vast catalog of genealogically rich records from all over the globe, but to introduce FamilySearch patrons to WorldCat.org’s vast offerings online.

“FamilySearch.org users taking full advantage of all the resources of WorldCat.org may find many additional resources to enlighten their understanding of their ancestors. Many of these records tell the story of their lives between their birth and death. This is a valued, ongoing relationship with OCLC, and we will certainly encourage everyone from novices to experienced researchers to explore the depths of WorldCat.org’s resources,” said David E. Rencher, chief genealogy officer, FamilySearch International.

WorldCat.org is a unique tool for users to research heritage and complements genealogy tools such as FamilySearch, Ancestry.com, and other genealogy research tools.

“Libraries are often the only source for local information about births, deaths, marriages, businesses, and other family histories.

WorldCat.org can be the bridge to uncovering this valuable genealogy information,” concluded Prichard.

To start exploring and to sign up for a WorldCat.org account, visit the site at http://www.worldcat.org.

About WorldCat.org

Since 2006, WorldCat.org has been the window to the collections and resources of more than 10,000 libraries in more than 100 countries around the world. WorldCat.org is a unique destination, representing the world’s largest library community on the web. WorldCat.org is an innovation of OCLC, a nonprofit global library organization that provides shared technology services, original research, and community programs to member libraries and the library community at large. OCLC, member libraries, publishers, and other partner organizations collaboratively maintain WorldCat.org. Explore WorldCat.org on the web.

About OCLC

OCLC is a nonprofit global library organization that provides shared technology services, original research, and community programs so that libraries can better fuel learning, research, and innovation. Through OCLC, member libraries cooperatively produce and maintain WorldCat, the most comprehensive global network of data about library collections and services. Libraries gain efficiencies through OCLC’s WorldShare, a complete set of library management applications and services built on an open, cloud-based platform. It is through collaboration and sharing of the world’s collected knowledge that libraries can help people find answers they need to solve problems. Together as OCLC, member libraries, staff, and partners make breakthroughs possible.

Share article on social media or email:

Science: Biology

Promontory Therapeutics Awarded “Cancer Immunology Solution of the Year” in 2022 BioTech Breakthrough Awards Program

Leave a comment


News Image

We are grateful to BioTech Breakthrough for this award, which recognizes the importance of immunogenic small molecules in cancer care – Robert Fallon, Promontory President and Chief Executive Officer


NEW YORK (PRWEB)

Promontory Therapeutics Inc., a clinical stage biotech company advancing small molecule immunotherapies in oncology, today announced it has received the “Cancer Immunology Solution of the Year” award in the second annual BioTech Breakthrough Awards program conducted by BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products and services around the globe.

Promontory Therapeutics is currently in Phase 2 clinical trials focused on the development of small molecule immunotherapy in cancer. Through its lead agent PT-112, the first ever conjugate of pyrophosphate in oncology, Promontory has realized advantages over the immune-oncology class of checkpoint inhibitors (CPIs) — including tolerability, pleiotropic mechanism of action, promotion of immunogenic cell death (ICD) and osteotropism (affinity to bone).

“We are grateful to BioTech Breakthrough for this award, which recognizes the importance of immunogenic small molecules in cancer care,” said Promontory President and Chief Executive Officer Robert Fallon. “Many patients do not respond to I-O checkpoint inhibitors, especially in solid tumors like late stage prostate cancer. Our drug candidate helps ignite the adaptive immune system and promotes clonal expansion of T-cells that lead to more durable therapeutic response.”

“ICD is a process that elicits an anti-cancer immune response related to the way in which a cancer cell dies. The induction of ICD is akin to viral mimicry and can be a critical factor in longer term response to therapy, whether alone or in combination with other immunotherapy agents,” said Bryan Vaughn, Managing Director of BioTech Breakthrough Awards. “Based upon preclinical models, PT-112 represents the potential best-in-class ICD inducing agent. PT-112’s immunogenic cell death induction makes it a promising future treatment option in several possible cancer indications including thymoma and lung cancers. Congratulations on this true breakthrough and being our choice for ‘Cancer Immunology Solution of the Year.’”

In three completed Phase 1 trials, PT-112 demonstrated single-agent anti-cancer activity and safety. The company is currently enrolling patients in multiple Phase 2 trials, including a late-stage metastatic castration-resistant prostate cancer study, a disease with limited treatment options that has yet to see widespread approval of immunotherapies. In 2022, PT-112’s ICD effects in human and animal tumors were further validated in peer-reviewed articles in both the Lancet’s eClinical Medicine and MDPI’s Cancers.

PT-112 also exhibits a unique property, osteotropism, making it a strong candidate for treating cancers that originate in or metastasize to the bone, such as prostate cancer and hematological malignancies. A Phase 1 study in multiple myeloma was recently completed, an indication in which PT-112 holds orphan drug status.

In collaboration with the National Cancer Institute, PT-112 monotherapy is being studied in thymoma and thymic carcinoma, a rare disease with no approved FDA therapy for which PT-112 has also received orphan drug designation. Promontory also has an ongoing collaboration with Pfizer and Merck KGaA studying PT-112 in combination with PD-L1 checkpoint inhibitor, avelumab, in non-small cell lung cancer (NSCLC).

The mission of the annual BioTech Breakthrough Awards program is to conduct the industry’s most comprehensive analysis and evaluation of the top companies, solutions and products in the life sciences and biotechnology industry today. This year’s program attracted more than 1,350 nominations from over 12 different countries throughout the world.

####

About Promontory Therapeutics

Promontory Therapeutics Inc. is a privately held, clinical stage pharmaceutical company focused on small molecule immunotherapy. The company’s lead candidate, PT-112, is the first small molecule conjugate of pyrophosphate in oncology, and possesses a unique pleiotropic mechanism of action that promotes immunogenic cell death (ICD), through the release of damage associated molecular patterns (DAMPs) that bind to pattern recognition receptors on dendritic cells and promote the adaptive immune response in the tumor microenvironment. Clinical data generated across three Phase 1 studies have demonstrated single-agent anti-cancer activity and an attractive tolerability profile, and three Phase 2 studies of PT-112 are underway. The company’s research and development work has been conducted in the United States, Europe and Asia, along with a sub-license agreement for the development, commercialization and use of PT-112 in Greater China. The company also sponsors the ongoing clinical study of PT-112 in combination with the PD-L1 inhibitor avelumab under a collaboration agreement with Pfizer and Merck KGaA, Darmstadt, Germany (operating as EMD Serono in the US and Canada), and has an active Phase 2 trial underway with the NCI utilizing PT-112 in thymic epithelial tumors where PT-112 has received Orphan Drug designation.

To learn more about Promontory Therapeutics, visit the company’s website here.

About BioTech Breakthrough

Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the BioTech Breakthrough Awards program is devoted to honoring excellence in life science and biotechnology solutions, services and companies. The BioTech Breakthrough Awards provide public recognition for the achievements of biotechnology companies and products in categories including BioPharma, Genomics, Therapeutics, Food Science and BioAgriculture, and more. For more information visit BioTechBreakthroughawards.com

Share article on social media or email:

Science: Biology

Molecular Devices announces ValitaTiter IgG quantitation assay to fast track biologics sample testing

Leave a comment


Using ValitaTiter with our SpectraMax microplate readers, SoftMax Pro Software, and automation solutions further enhances the reliability and reproducibility of assay results and enables seamless integration of the assay in regulated workflows.


SAN JOSE, Calif. (PRWEB)

Molecular Devices announced today the launch of the ValitaCell IgG titer assay, ValitaTiter, available for sale across North America and Europe. The new assay will complement Molecular Devices’ workflow solution for cell line development by offering a 10-minute titer assay that can be run on the company’s SpectraMax series of microplate readers.

Producing rapid results compared to HPLC, ELISA, and Biolayer Interferometry, ValitaTiter is the most efficient assay for minimizing cost and time to results because it works in the presence of cells, minimizes dilutions, eliminates wash steps, and easily integrates into automated high-throughput cell line development and process development workflows. Integrating ValitaTiter and Molecular Devices fluorescence polarization plate readers produce a seamless IgG titer assay setup and optimization process allowing teams to realize savings on time and resources as well as faster time-to-market.

Molecular Devices’ technical support team and PhD-level field application scientists partner with their customers to create complete automated workflows to shorten the time to market for critical vaccines and therapeutics. This workflow will now include the ValitaTiter IgG assay. Molecular Devices’ long history of developing regulatory compliance solutions and software will ensure a streamlined regulatory and validation process.

“Integrating ValitaTiter gives us a great opportunity to expand our cell line development workflow even further, to bring therapeutics to market faster,” said Terrell Mathews, Vice ​President of Global Sales at Molecular Devices. “Using ValitaTiter with our SpectraMax microplate readers, SoftMax Pro Software, and automation solutions further enhances the reliability and reproducibility of assay results and enables seamless integration of the assay in regulated workflows.”

Learn more about the ValitaTiter IgG quantitation assay from Molecular Devices here.

About Molecular Devices, LLC

Molecular Devices is one of the world’s leading providers of high-performance bioanalytical measurement systems, software, and consumables for life science research, pharmaceutical and biotherapeutic development. Included within a broad product portfolio are platforms for high-throughput screening, genomic and cellular analysis, colony selection, and microplate detection. These leading-edge products enable scientists to improve productivity and effectiveness, ultimately accelerating research and the discovery of new therapeutics. Molecular Devices is committed to the continuous development of innovative solutions for life science applications. The company is headquartered in Silicon Valley, California with offices around the globe.

About ValitaCell

ValitaCell’s mission is to accelerate the pace and reduce the cost of manufacturing innovative medicines. We are focused on enabling our biopharmaceutical customers to bring medicines to the patients that need them most, in the shortest length of time. Most drugs that advance to clinical trial fail before they make it to the market. This failure increases costs and delays lifesaving treatments for patients. Our team is focused on creating analytical technologies that empower scientists with rich cell data and insights earlier in the drug discovery and development process. We are committed to advancing human healthcare worldwide. In September 2022, ValitaCell was acquired by Beckman Coulter Life Sciences.

Valita and Valita Titer are trademarks of ValitaCell.

SpectraMax and SoftMax are trademarks of Molecular Devices, LLC.

Share article on social media or email:

Science: Biology

Meeting the Increasing Manufacturing Demands of the Rapidly Growing Cell and Gene Therapy and Vaccine Markets, Upcoming Webinar Hosted by Xtalks

Leave a comment


The speakers will discuss the cGMP quality controls and the full suite of pDNA-centered, in-house analytical development, qualification, and validation capabilities.


TORONTO, Ontario (PRWEB)

Join this webinar to discuss the growing cell and gene therapy and vaccine markets, the resulting critical bottlenecks in plasmid (pDNA) production, and how these bottlenecks are being addressed by collaborations and partnerships between some of the key contributors to the biomanufacturing supply chain.

The featured speakers will give an overview of the manufacturing process for adeno-associated virus (AAV) and highlight how Akron Bio’s new facility is designed to address the serious industry issues around capacity, scalability, and quality. The speakers will discuss the cGMP quality controls and the full suite of pDNA-centered, in-house analytical development, qualification, and validation capabilities. Attendees will learn about full-scale engineering and process validation capabilities enabling cGMP production, completion of clinical trials, and approved therapy commercialization.

Register to learn about meeting the increasing manufacturing demands of the rapidly growing cell and gene therapy and vaccine markets.

Join Ana Martini (webinar moderator), PhD, Associate Director, Program Management, Akron Bio; Andrea O’Hara, PhD, Strategic Technical Specialist, Next-Generation Sequencing, Azenta Life Sciences; Ian Hart, VP of Operations, Akron Bio; and Kurt Herzog, Director of Process Scale-up, AstraZeneca, for the live webinar on Friday, November 11, 2022, at 11am EST (4pm GMT/UK).

For more information, or to register for this event, visit Meeting the Increasing Manufacturing Demands of the Rapidly Growing Cell and Gene Therapy and Vaccine Markets.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email:

Science: Biology

Shoreline Biome Announces Name Change to Intus Biosciences

Leave a comment


News Image


FARMINGTON, Conn. (PRWEB)

Shoreline Biome, the developer of the industry-leading Titan-1TM microbiome research, discovery and testing platform, announced today that it has changed its name to Intus Biosciences.

Intus—a Latin word for “inside”— reflects the company’s focus on making advances in health and wellbeing by working inside the bacterial microbiome. The change marks Intus Biosciences’ strategic transformation from supplying research tools to providing complete data-driven solutions for microbiome discovery and understanding. The company’s unique and scalable Titan-1TM platform powers “sample to answer” services for pharmaceutical, diagnostic, and research partners, and supports cutting-edge testing for commercial laboratories to identify and track bacteria in unprecedented detail.

Intus Biosciences’ groundbreaking platform is a combination of patented assays and advanced proprietary analysis tools. Its ability to generate accurate, high-resolution (i.e., strain-level) data on a high-throughput basis is unprecedented. As the power of the technology has become known across the healthcare sector, partner and client demand for advanced services producing clear and actionable results, has driven the changes being announced today.

Shoreline Biome was founded by a team of scientists dedicated to making the microbiome as essential to healthcare as it is to our health. To overcome the issues that limit progress across the microbiome industry, they applied their deep expertise in next-generation sequencing to develop the technologies which today form the Titan-1TM platform.

“This is an incredibly exciting time for our company and the amazing team behind it,” said Paul Denslow, Intus Biosciences’ CEO. “An unmatched ability to produce actionable insights into the role of bacteria in the body and beyond, allows us to make extraordinary contributions across healthcare. Partners and clients have continually challenged us to deliver our highly differentiated technology in ever more creative and exciting ways. This has driven the shift to a data-centric platform model which our new name and dynamic branding reflect well.”

About Intus Biosciences, LLC

Intus Biosciences’ world-leading technology identifies bacteria and delivers answers about the microbiome with unprecedented detail, accuracy and scale. Its patented, validated Titan-1TM platform combines high-throughput assay and analysis technology and is unique in generating strain-level information. The company provides research and commercial services across global pharmaceutical, diagnostic, and testing industries; is active in health, agricultural, and environmental fields; and continues to develop innovative new partnerships, technologies, and applications.

To learn more or to partner with Intus Biosciences, visit intusbio.com.

Share article on social media or email: